Mangoceuticals以250万美元的注册直接发行价定价，并附有认购证

2025-12-18 21:53

Mangoceuticals (MGRX) entered into definitive agreements with institutional investors for a registered direct offering and concurrent private placement with aggregate gross proceeds of ~$2.5M.
The transaction includes the sale of 1.93M common units or pre-funded units, each consisting of one share of common stock or pre-funded warrant and one PIPE common warrant.
Each PIPE common warrant is exercisable for one share of common stock at an exercise price of $1.4245.
The offering price is $1.295/common unit and $1.295 per pre-funded unit, with pre-funded warrants exercisable immediately.
The transactions are expected to close on or about December 19, 2025.
Net proceeds will be used for general corporate purposes and working capital.
MGRX shares down 5% premarket.

More on Mangoceuticals